Board summary
Key figures
49,899
Registered population
56.4% aged 18–64
25.5%
Aged 65+
ICB 19.0% · England 17.9%
3.3%
Ethnic minority (non-White)
1.2% Asian · England 9.6%
5.2%
In IMD quintile 1
ICB 31.9% · England 21.0%
~2,627
Core20 residents (est.)
Resident basis; registered basis ~2,647 · see page 3
8,836
Hypertension register
+6.99% in 3 yrs · England +5.60%
438
SMI register
11.1% of Cheshire East (LAD)'s
916
COPD register
Reviews -6.00% in 3 yrs
Forecast to 2030
10,599
Hypertension patients, 2030
+1,763 on today
67.1%
QRISK ≥20% on statins, 2030
+3.49pp over 3 yrs
6.3%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Under-80 blood pressure and lipid control lag.
Under-80 BP control is 64.0% (England 67.8%) after a -5.9% three-year change, while QRISK ≥ 20% lipid therapy is 59.5% (England 63.6%).
Screening and childhood vaccination exceed national rates.
Breast screening reaches 76.9% (England 69.9%), cervical screening aged 25-49 reaches 76.3% (England 66.8%), and age-5 MMR1 reaches 99.2% (England 91.7%).
Population, age and ethnicity
Adults aged 65+ make up 25.5% of the list, well above England's 17.9%
CHOC (CONGLETON & HOLMES CHAPEL) PCN registers 49,899 patients, with 25.5% (12,711) aged 65+, above Cheshire East (22.6%), the ICB (19.0%) and England (17.9%). Patients aged 18-64 comprise 56.4% and aged 0-17 represent 18.2%. Projected list growth to 2030 is 3.6% (England 2.3%), with unverified projection methodology. Census usual residents are 96.7% White and 3.3% ethnic minority groups. Recorded learning disability prevalence is 0.4% (195 patients), below Cheshire East (0.5%) and England (0.6%).
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Cheshire East (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Cheshire East LA) | 2,129 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 81.2% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 60.5% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Cheshire East LA) | 939 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Cheshire East LA) | 14.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation averages 5.2% in the PCN, spanning 10.2 percentage points across practices
The PCN Core20 share is 5.2%, below England (21.0%), Cheshire East (9.2%) and the ICB (31.9%), with an average IMD decile of 7.5. Practice shares span 10.2 percentage points: Lawton House Surgery has 10.2% (1,357 estimated patients), Meadowside Medical Centre 6.3% (549 estimated patients), Readesmoor Medical Group Practice 5.0% (741 estimated patients), and The Health Centre (holmes Chapel) 0.0%. Resident Core20 estimates total 2,627, while practice estimates sum to 2,647. Deprivation concentrates in Lawton House Surgery, holding the highest share and largest patient volume.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
438
SMI register
0.89% recorded prevalence
195
Learning disability register
0.40% recorded prevalence
14
Care homes, 588 beds
In the PCN catchment
8.8%
Provide unpaid care
Cheshire East (LAD), Census 2021
Recorded severe mental illness prevalence is 0.9% (438 patients; England 1.0%). The PCN catchment contains 14 care homes with 588 beds, though bed capacity does not establish registered resident numbers. Cheshire East local authority data records 10 people sleeping rough in 2025 and an 8.8% unpaid carer rate, yielding an estimated ceiling of 4,391 carers that cannot be directly extrapolated to registered patients.
Severe mental illness: physical health checks
Severe mental illness prevalence is 0.9% (England 1.0%). Blood pressure checks reached 78.5% (England 83.4%), with Readesmoor Medical Group Practice at 68.4%. Recorded BMI reached 75.4% (England 82.1%), with Readesmoor at 54.7%.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
8,836
Hypertension register
+6.99%
Register growth, 3 yrs
Cheshire East (LAD) +6.54% · England +5.60%
−4.03pp
BP control, under 80
≤140/90 · −0.62pp aged 80+
+1,763
More patients by 2030
Forecast 10,599 (20.51%)
Hypertension case-finding and control
Hypertension recorded prevalence is 17.9% (8,836 patients), above Cheshire East (17.3%), the ICB (16.8%) and England (15.2%). Blood pressure control under age 80 is 64.0%, trailing Cheshire East (66.6%), the ICB (66.4%) and England (67.8%), following a 5.9% three-year decline (England +3.2%). At Readesmoor Medical Group Practice, control under 80 is 54.1%. Hypertension treated to target is 68.3% (England 70.3%). Unadjusted registers cannot confirm unmet need, and observation periods are unstated. Lower blood pressure control alongside higher prevalence could reflect treatment optimisation or follow-up gaps, testable via clinical audit.
Lipids and statins
Patients with QRISK ≥ 20% on lipid-lowering therapy reach 59.5%, below Cheshire East (61.2%), the ICB (63.2%) and England (63.6%). Statin therapy in diabetes without CVD is 68.3% (England 73.2%). Lower lipid therapy uptake may reflect follow-up gaps, testable via primary prevention audit.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 115,876 | £1.70 | £1.71 | £1.86 | £196,989 |
| Cardiovascular (all), 2025 | 151,011 | £3.47 | £4.37 | £3.33 | £524,008 |
For lipid-regulating drugs in 2026, the PCN prescribed 115,876 items at £1.70 per item (spend £196,989), below Cheshire East (£1.72), the ICB (£1.71) and England (£1.86). The PCN spends £18,540 less than at England's unit cost. Lower unit costs do not establish prescribing efficiency.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+3.16%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−1.61%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 1.9% across 916 patients (England 1.9%). Twelve-month COPD reviews fell 6.0% over three years to 73.8% (England +2.8% to 76.4%). Asthma prevalence is 7.3% across 3,411 patients (England 6.6%), where 71.4% had a review in 12 months (England 65.7%), leaving 975 unreviewed. This divergence could reflect review capacity allocation, testable via clinical audit.
Cancer register and children's immunisation
Cancer prevalence is 5.1% across 2,493 patients (Cheshire East 4.9%, England 3.8%). Childhood immunisation coverage is high: age-5 MMR dose 1 is 99.2% and dose 2 is 95.8%, reflecting a 3.4 pp dose difference. The 4-in-1 pre-school booster reached 94.9% (England 80.9%), below the 95.0% target by 0.1 pp.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
In 2022, 55.5% of staged cancers across NHS Cheshire and Merseyside ICB (7,482 of 13,490) were diagnosed at stage 1 or 2, in line with England (55.3%) but 19.5 pp below the 75.0% national ambition by 2028. Staged cancers represented 72.8% of all 18,522 registered cancers (England 67.0%). Closing the gap to 75.0% would require about 2,640 extra early-stage cases annually across the ICB. Meanwhile, PCN cancer prevalence reached 5.1% (2,493 patients), with three-year growth of +11.5% (England +9.0%). These figures reflect wider ICB staging rather than PCN delivery. System-wide early staging shortfalls indicate that despite high local recorded cancer prevalence, late diagnosis remains a pathway risk across the wider.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), East Cheshire NHS Trust met the 62-day cancer standard for 53.4% of pathways, 31.6 pp below the 85.0% standard, trailing Mid Cheshire Hospitals NHS Foundation Trust (71.1%), University Hospitals of North Midlands NHS Trust (68.8%), the ICB (76.2%) and England (71.2%). Conversely, 28-day faster diagnosis reached 81.1% (standard 75.0%) and 31-day combined treatment reached 96.3% (standard 96.0%). In diagnostics, 26.6% of MRI patients waited 6+ weeks (England 21.4%), whereas colonoscopy 6+ week waits were 10.8% (England 30.8%). Provider waits reflect acute system pressures rather than PCN performance.
| Pathways within standard (%) | East Cheshire | Mid Cheshire | of North Midlands | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 81.08 | 79.95 | 80.65 | 77.25 | 79.32 |
| 31-day treatment (96%) | 96.30 | 86.21 | 93.85 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 53.41 | 71.12 | 68.84 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Cheshire | Mid Cheshire | of North Midlands | England |
|---|---|---|---|---|
| MRI | 26.62 | 5.15 | 36.13 | 21.40 |
| CT | 11.49 | 1.09 | 2.86 | 9.92 |
| Echocardiography | 26.24 | 5.51 | 45.39 | 28.48 |
| Colonoscopy | 10.85 | 30.34 | 46.53 | 30.83 |
| Gastroscopy | 10.25 | 31.89 | 15.49 | 29.02 |
| All 15 DM01 tests | 16.17 | 12.72 | 22.94 | 23.14 |
| Community services activity | Cheshire East residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 72,825 | 541,280 |
| Referrals | 18,280 | 97,150 |
| Patients with a contact | 21,910 | 146,240 |
Community services (residents of Cheshire East), Jun 2026 (provisional). In Jun 2026 (provisional), adults aged 65+ accounted for 60.8% of community service contacts among Cheshire East residents (44,295 of 72,825 contacts). This substantial older-age share is consistent with heavy local community nursing and therapy demand, although the data captures local authority residents rather than registered PCN patients.
Practice variation and patient experience
Phone access spans 15.8 pp between practices despite uniformly high QOF clinical achievement
In 2025/26, overall QOF achievement reached 98.6% at Lawton House Surgery and 96.7% at Meadowside Medical Centre (England 92.5%). Clinical-domain achievement was 100.0% at Lawton House Surgery and 98.5% at Meadowside Medical Centre. Vaccination domain achievement spanned 10.0 pp, from 77.7% at Readesmoor Medical Group Practice to 87.7% at Lawton House Surgery (England 55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| (holmes Chapel) | 111 | 0.0 | 42.5% | 66.3% | 87.8% |
| Lawton House | 126 | 10.2 | 39.8% | 66.9% | 80.7% |
| Meadowside | 89 | 6.3 | 55.6% | 70.9% | 75.1% |
| Readesmoor | 105 | 5.0 | 54.1% | 67.4% | 72.4% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Seventeen of 25 measures trail England over three years despite heart failure gains
Across 25 monitored indicators, 17 trail England's three-year change. The widest relative lags occur in blood pressure control under 80, which fell 5.9% (England +3.2%), COPD reviews, falling 6.0% (England +2.8%), and dementia register prevalence, falling 2.2% (England +6.0%). Severe mental illness alcohol recording also fell 1.9 pp (England +5.4 pp). Conversely, heart failure reviews grew +18.3% over three years versus +8.7% in England, and smoking cessation support rose +1.4 pp (England +0.1 pp). Trailing national trajectories across reviews and blood pressure control could reflect review capacity or follow-up gaps, testable via clinical audit.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
BP control, under 80
COPD reviews
Dementia register
Hypertension treated to target
Alcohol record (psychosis)
Heart failure reviews
Smoking support (SMI)
Cervical screening
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Cheshire East (LAD) | Asset | PCN | Cheshire East (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 14 (588 beds) | n/a | Schools (catchment) | 55 | n/a |
| Children's centres | 1 | 14 | Places of worship | 46 | 272 |
| Libraries | 2 | 16 | Day centres (VCS) | n/a | 1 |
| Children and young people (VCS) | n/a | 1 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 5 | 41 | Primary academies | 14 | 78 |
| Special schools | n/a | 5 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension and lipid review recall
Across 8,836 hypertension patients (17.9%), under-80 BP control is 64.0% (England 67.8%, -5.9% vs +3.2%; Readesmoor Medical Group Practice 54.1%), and QRISK >= 20% lipid therapy is 59.5% (England 63.6%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
SMI physical health check outreach
Across 438 SMI patients (0.9%), BP checks are 78.5% (England 83.4%) and BMI checks are 75.4% (England 82.1%); Readesmoor Medical Group Practice recorded 68.4% and 54.7%. For discussion: the PCN could introduce combined physical health check appointments, review template coding, and raise shared care pathways with system partners. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Respiratory annual review recall alignment
COPD reviews across 916 patients (1.9%) fell 6.0% to 73.8% (England +2.8% to 76.4%); asthma reviews across 3,411 patients (7.3%) reached 71.4% (England 65.7%), leaving 975 unreviewed. For discussion: practices could standardise respiratory recall templates and align annual COPD and asthma review slots with inhaler prescribing checks. Low cost, quick to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Learning disability register review (p2) | Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Physical health check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension blood pressure control audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall audit (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Early diagnosis safety netting audit (p7) | Cancers diagnosed at stage 1 or 2 (All cancer sites) | — | ICB |
| Telephone triage and access review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Hypertension and lipid review recall (p12) | Hypertension register · Hypertension: QOF prevalence · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 2 · SMI physical health check outreach (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN & Practice |
| Option 3 · Respiratory annual review recall alignment (p12) | COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 months | Core20PLUS5 respiratory | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
